Your browser doesn't support javascript.
loading
Performance and effectiveness of hepatocellular carcinoma screening in individuals with HBsAg seropositivity in China: a multicenter prospective study.
Zeng, Hongmei; Cao, Maomao; Xia, Changfa; Wang, Dongmei; Chen, Kun; Zhu, Zheng; Fu, Ruiying; Zhang, Shaokai; Zhou, Jinyi; Wang, Huadong; Qi, Xianyun; Dai, Shuguang; Chen, Yong; Sun, Zhong; Ding, Hao; Li, Qingwen; Zhao, Hui; Zhang, Xuehong; Morze, Jakub; Ji, John S; Sun, Feng; Yu, Xueqin; Qu, Chunfeng; Chen, Wanqing.
Afiliación
  • Zeng H; National Central Cancer Registry, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.
  • Cao M; Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.
  • Xia C; Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.
  • Wang D; State Key Laboratory of Molecular Oncology and Department of Immunology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.
  • Chen K; State Key Laboratory of Molecular Oncology and Department of Immunology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.
  • Zhu Z; Department of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.
  • Fu R; National Central Cancer Registry, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.
  • Zhang S; Department of Cancer Epidemiology, Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital, Henan Engineering Research Center of Cancer Prevention and Control, Henan International Joint Laboratory of Cancer Prevention, Zhengzhou, People's Republic of China.
  • Zhou J; Department for Chronic Non-communicable Diseases Control, Jiangsu Provincial Center for Disease Control and Prevention (Public Health Research Institute of Jiangsu Province), Nanjing, People's Republic of China.
  • Wang H; Department of Chronic Non-communicable Diseases Prevention and Treatment, Anhui Provincial Center for Disease Control and Prevention, Hefei, People's Republic of China.
  • Qi X; Department of Chronic Non-communicable Diseases Prevention and Treatment, Yingdong Center for Disease Control and Prevention, Fuyang, People's Republic of China.
  • Dai S; Sheyang Center for Disease Control and Prevention, Yancheng, People's Republic of China.
  • Chen Y; Binhai Center for Disease Control and Prevention, Yancheng, People's Republic of China.
  • Sun Z; Dancheng Center for Disease Control and Prevention, Zhoukou, People's Republic of China.
  • Ding H; Mengcheng Center for Disease Control and Prevention, Bozhou, People's Republic of China.
  • Li Q; Shenqiu Center for Disease Control and Prevention, Zhoukou, People's Republic of China.
  • Zhao H; Lingbi Center for Disease Control and Prevention, Suzhou, People's Republic of China.
  • Zhang X; Department of Nutrition, Harvard University, Cambridge, MA, USA.
  • Morze J; Department of Cardiology and Internal Medicine, College of Medical Sciences, SGMK University, Olsztyn, Poland.
  • Ji JS; Vanke School of Public Health, Tsinghua University, Beijing, People's Republic of China.
  • Sun F; Department of Epidemiology and Biostatistics, Peking University, Beijing, People's Republic of China.
  • Yu X; The Daffodil Centre, The University of Sydney, Sydney, New South Wales, Australia.
  • Qu C; State Key Laboratory of Molecular Oncology and Department of Immunology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China. quchf@cicams.ac.cn.
  • Chen W; Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China. chenwq@cicams.ac.cn.
Nat Cancer ; 4(9): 1382-1394, 2023 09.
Article en En | MEDLINE | ID: mdl-37667043
ABSTRACT
Current guidelines recommend hepatocellular carcinoma (HCC) surveillance for at-risk individuals, including individuals with hepatitis B virus infection. However, the performance and survival benefits of annual screening have not been evaluated through multicenter prospective studies in a Chinese population. Between 2017 and 2021, we included 14,426 participants with hepatitis B surface antigen seropositivity in an annual HCC screening study in China using a multicenter prospective design with ultrasonography and serum alpha-fetoprotein. After four rounds of screening and follow-up, the adjusted hazard ratios of death after correction for lead-time and length-time biases for screen-detected cancers at the prevalent and incident rounds were 0.74 (95% confidence interval = 0.60-0.91) and 0.52 (95% confidence interval = 0.40-0.68), respectively. A meta-analysis demonstrated that HCC screening was associated with improved survival after adjusting for lead-time bias. Our findings highlight the 'real-world' feasibility and effectiveness of annual HCC screening in community settings for the early detection of HCC and to improve survival.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma Hepatocelular / Hepatitis B / Neoplasias Hepáticas Tipo de estudio: Clinical_trials / Diagnostic_studies / Observational_studies / Risk_factors_studies / Screening_studies / Systematic_reviews Límite: Humans País/Región como asunto: Asia Idioma: En Revista: Nat Cancer Año: 2023 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma Hepatocelular / Hepatitis B / Neoplasias Hepáticas Tipo de estudio: Clinical_trials / Diagnostic_studies / Observational_studies / Risk_factors_studies / Screening_studies / Systematic_reviews Límite: Humans País/Región como asunto: Asia Idioma: En Revista: Nat Cancer Año: 2023 Tipo del documento: Article
...